Globus Medical: Straightening Its Back
Globus Medical has rebounded strongly, driven by accelerating earnings and successful integration of acquisitions like NuVasive and Nevro. The company delivered on robust Q3 results, with 7% organic g...
Fiscal Year: January - December
Globus Medical, Inc. (GMED), listed on the NYSE, has a market capitalization of $. As of Dec 07, 2025, the stock is trading at $91.10 per share, offering investors a clear view of its current market value. Globus Medical, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 29.58, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Globus Medical, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Globus Medical, Inc. (GMED) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Globus Medical, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Globus Medical, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Globus Medical, Inc. is 21.04, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Globus Medical, Inc. (GMED) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Globus Medical, Inc. (GMED) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Globus Medical, Inc. (GMED) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Globus Medical, Inc.. To access the full SS Score, consider upgrading your subscription.
Globus Medical, Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 29.58. Investors should compare these metrics with industry peers to gauge whether Globus Medical, Inc. is outperforming or underperforming within its sector.
Globus Medical has rebounded strongly, driven by accelerating earnings and successful integration of acquisitions like NuVasive and Nevro. The company delivered on robust Q3 results, with 7% organic g...
Shares of the medical technology company are headed for their largest same-day percentage increase on record.
Globus Medical, Inc. ( GMED) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Brian Kearns - Senior Vice President of Business Development & Investor Relations Keith Pfeil - CE...
AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30...
Here's why we believe Globus Medical (GMED) stock merits attention as a value stock. It's currently trading approximately 33% below its 1-year high and is also trading at a PS multiple that falls belo...
AUDUBON, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended Septembe...
AUDUBON, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, has announced the launch of the ANTHEM™ Elbow Fracture System, a fully c...
AUDUBON, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, announced that a Delaware jury has returned a verdict in favor of Globu...
Globus Medical, Inc. (NYSE:GMED) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Brian J. Kearns - Senior Vice President of Business Development & Investor Relations D...
Globus Medical (GMED) Q2 Revenue Up 18%
AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 202...
AUDUBON, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Opera...
AUDUBON, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30...
AUDUBON, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its n...
Globus Medical shares have reset after a soft Q1 and Nevro acquisition, making valuations more attractive despite near-term dilution. The company's strong growth, driven by NuVasive integration and pr...
AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurc...
Investors can contact the law firm at no cost to learn more about recovering their losses
Globus Medical, Inc. (NYSE:GMED) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development & IR Dan Scavilla - President & CEO Keith Pfeil ...
AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 202...
AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 3...
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition...
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro...
AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced two commercial launches: COHERE™ ALIF Spacer: The firs...
AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the ...
AUDUBON, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Canaccord Genuit...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 283.85M | -29.95% | Est @-29.9% |
| 2026 | 162.50M | -42.75% | Analyst x1 |
| 2027 | 145.86M | -10.24% | Est @-10.2% |
| 2028 | 136.55M | -6.38% | Est @-6.4% |
| 2029 | 131.51M | -3.69% | Est @-3.7% |
| 2030 | 129.29M | -1.69% | Est @-1.7% |
| 2031 | 128.71M | -0.45% | Est @-0.5% |
| 2032 | 129.25M | 0.42% | Est @0.4% |
| 2033 | 130.58M | 1.03% | Est @1.0% |
| 2034 | 132.35M | 1.36% | Est @1.4% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 165.23M | 1.00 | 165.23M |
| 2024A | 405.21M | 1.00 | 405.21M |
| 2025E | 283.85M | 1.09 | 260.48M |
| 2026E | 162.50M | 1.19 | 136.84M |
| 2027E | 145.86M | 1.29 | 112.71M |
| 2028E | 136.55M | 1.41 | 96.82M |
| 2029E | 131.51M | 1.54 | 85.57M |
| 2030E | 129.29M | 1.67 | 77.20M |
| 2031E | 128.71M | 1.83 | 70.52M |
| 2032E | 129.25M | 1.99 | 64.99M |
| 2033E | 130.58M | 2.17 | 60.25M |
| 2034E | 132.35M | 2.36 | 56.03M |
| Terminal | 2.10B | 2.36 | 887.01M |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.